Duopharma Biotech Berhad (KLSE: DPHARMA)

Duopharma Biotech Berhad Statistics

Total Valuation

Duopharma Biotech Berhad has a market cap or net worth of MYR 1.14 billion. The enterprise value is 1.45 billion.

Market Cap	1.14B
Enterprise Value	1.45B

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	Aug 29, 2024

Share Statistics

Duopharma Biotech Berhad has 961.94 million shares outstanding. The number of shares has increased by 0.74% in one year.

Shares Outstanding	961.94M
Shares Change (YoY)	+0.74%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.31%
Owned by Institutions (%)	21.58%
Float	454.59M

Valuation Ratios

The trailing PE ratio is 23.16 and the forward PE ratio is 14.51. Duopharma Biotech Berhad's PEG ratio is 0.78.

PE Ratio	23.16
Forward PE	14.51
PS Ratio	1.53
PB Ratio	1.65
P/FCF Ratio	43.39
PEG Ratio	0.78

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.78, with an EV/FCF ratio of 54.93.

EV / Earnings	29.31
EV / Sales	1.94
EV / EBITDA	11.78
EV / EBIT	18.01
EV / FCF	54.93

Financial Position

The company has a current ratio of 4.35, with a Debt / Equity ratio of 75.74.

Current Ratio	4.35
Quick Ratio	2.93
Debt / Equity	75.74
Debt / EBITDA	4.27
Debt / FCF	19.92
Interest Coverage	3.31

Financial Efficiency

Return on equity (ROE) is 7.23% and return on invested capital (ROIC) is 4.32%.

Return on Equity (ROE)	7.23%
Return on Assets (ROA)	3.88%
Return on Capital (ROIC)	4.32%
Revenue Per Employee	453,350
Profits Per Employee	29,963
Employee Count	1,650
Asset Turnover	0.58
Inventory Turnover	1.99

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.43% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+4.43%
50-Day Moving Average	1.21
200-Day Moving Average	1.23
Relative Strength Index (RSI)	41.04
Average Volume (20 Days)	663,120

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Duopharma Biotech Berhad had revenue of MYR 748.03 million and earned 49.44 million in profits. Earnings per share was 0.05.

Revenue	748.03M
Gross Profit	269.13M
Operating Income	80.48M
Pretax Income	60.52M
Net Income	49.44M
EBITDA	119.57M
EBIT	80.48M
Earnings Per Share (EPS)	0.05

Balance Sheet

The company has 221.16 million in cash and 525.57 million in debt, giving a net cash position of -304.41 million or -0.32 per share.

Cash & Cash Equivalents	221.16M
Total Debt	525.57M
Net Cash	-304.41M
Net Cash Per Share	-0.32
Equity (Book Value)	693.95M
Book Value Per Share	0.72
Working Capital	536.93M

Cash Flow

In the last 12 months, operating cash flow was 52.53 million and capital expenditures -26.15 million, giving a free cash flow of 26.38 million.

Operating Cash Flow	52.53M
Capital Expenditures	-26.15M
Free Cash Flow	26.38M
FCF Per Share	0.03

Margins

Gross margin is 35.98%, with operating and profit margins of 10.76% and 6.61%.

Gross Margin	35.98%
Operating Margin	10.76%
Pretax Margin	8.09%
Profit Margin	6.61%
EBITDA Margin	15.98%
EBIT Margin	10.76%
FCF Margin	3.53%

Dividends & Yields

This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.37%.

Dividend Per Share	0.03
Dividend Yield	2.37%
Dividend Growth (YoY)	21.74%
Years of Dividend Growth	n/a
Payout Ratio	44.75%
Buyback Yield	-0.74%
Shareholder Yield	1.63%
Earnings Yield	4.32%
FCF Yield	2.30%

Stock Splits

The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.

Last Split Date	Sep 6, 2021
Split Type	Forward
Split Ratio	1.3333333333